CGBIO_JP
CGBIO
Menu
  • CGBIOについて
    • 紹介
    • 代表挨拶
    • 事業内容
    • 海外事業
    • 主な経歴
  • 研究開発
    • 研究所紹介
    • 研究分野
    • 特許
    • 論文
  • 製品紹介
    • 一覧
    • Orthopedic
    • Wound
    • Aesthetics
    • Dental
  • JP
    • KOR
    • ENG
    • CN
    • TH
    • ID
    • ES
Open
Close
Sitemap
시지바이오 사이트맵 닫기
CGBIOについて
紹介
代表挨拶
事業紹介
グローバル事業
主な経歴
研究開発
研究所紹介
研究分野
特許
論文
製品紹介
一覧
Orthopedic
  • NOVOSIS
  • MEDICLORE
  • BONGENER
  • EXCELOS INJECT
  • NOVOMAX
Wound
  • CURAVAC
  • CURASYS
  • EASYDEWMD保湿クリーム
AESTHETICS
  • GISELLELIGNE
  • CELLUNIT
Dental
  • BONGROS
  • CG OSS
home

R & D

Wound

  • 研究所紹介
  • 研究分野
  • 特許
  • 論文
Research Info
The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results
  • 2015-03-19
  • cgbio
  • 조회수Views : 922 views

Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al.

The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results.

Int Wound J 2009; 6(2): 159-66.

NEXT
Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial
PREV
Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells
LIST

Head Office : F3, 211, Itaewon-ro, Yongsan-gu, Seoul, Korea
Research Institute : 244, Galmachi-ro,Jungwon-gu,Seongnam-si, Gyeonggi-do,Korea
Head Office TEL. +82-2-550-8300

Copyright All Right Reserverd By CGbio

인스타그램 페이스북

  • Family site
    • DaewoongPhamercy
    • Daewoong Bio
    • DNC
    • Bio-Alpha

to be updated.

OK close